Navigation Links
Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm
Date:4/22/2009

DALLAS, April 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that MuGard(TM), its proprietary polymer-based oral mucositis product has been launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and critical care.

Under a license from Access Pharmaceuticals Inc, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. In October 2008, MuGard was granted CE Mark certification by the Dutch Notified Body (KEMA). SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months. Access will receive significant royalties on net sales.

"SpePharm and Access are pleased with the commercial launch of MuGard in Europe, and while it is still in the early days, initial feedback has been positive," said Phillip Wise, Vice President of Business Development at Access. "SpePharm is also working hard to secure reimbursement from the individual governmental regulators, which we believe will greatly enhance initial product adoption and ongoing marketing efforts to reach and penetrate the target population of patients requiring this important treatment option. We look forward to further commercial launches from our other MuGard commercialization partners," he continued.

MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevent
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
2. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
3. New organic material may speed Internet access
4. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
5. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
6. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
7. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
8. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
9. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
10. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
11. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Propanc Health Group Corporation (OTCBB: ... on the development of cancer treatments for patients ... product includes PRP, a patented formulation consisting of ... well as the enzyme amylase designed to synergistically ... combination of anti-cancer agents working in combination with ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced ... quarter 2015 on Thursday, May 7, 2015 after the ... webcast and conference call for 4.30 pm ET (1.30 ... Live audio of the conference call will be webcast ... members of the news media and the general public. ...
(Date:4/22/2015)... , April 22, 2015 Steep ... analytics, announced today that it has opened an ... continued growth and expansion.  The common stock investment ... Section 506(c), a law intended to encourage funding ... Prior to 506(c), small businesses largely relied on ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Amex: NBS ) ("NeoStem" or the "Company"), an ... today announced that the Company and its wholly-owned subsidiary, Progenitor ... conferences: the 2011 World Stem Cell Summit, the AABB Annual ... 2011 World Stem Cell Summit – ...
... Oct. 4, 2011 Exosome Diagnostics, a leading ... in personalized medicine, today announced the appointment of ... Donovan, M.D., Ph.D., as chief medical officer, and ...  Raphael Bueno, M.D., associate chief of cardiothoracic surgery ...
... have discovered two early-stage phases of carbon nanotube growth ... tangle of tube growth that ultimately yields to orderly ... in the latest edition of the journal Nanotechnology ... Professor of Physics Zhifeng Ren and researcher Dr. Hengzhi ...
Cached Biology Technology:NeoStem Announces Participation in Multiple October Conferences 2NeoStem Announces Participation in Multiple October Conferences 3NeoStem Announces Participation in Multiple October Conferences 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Boston College Researchers discover 2 early stages of carbon nanotube growth 2
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Cancer Cell describes a small molecule inhibitor of polo-like kinase1 ... cancer therapy. The compound, ON01910, is a potent inhibitor of ... toxicity. The results of this study have led to clinical ... Plk1 is a molecule that plays a key role in ...
... proteins called phosphatases play a key role in the ... fruit flies and mice by researchers at the University ... collaboration with scientists at the Salk Institute, La Jolla, ... stem cells and for silencing expression of neuronal genes ...
... toward understanding the regulation of blood stem cells and ... research study published in the February issue of Developmental ... to examine the role of a key gene known ... from this research will be useful for future studies ...
Cached Biology News:New drug shows promise as powerful anticancer agent 2New insight into regulation of blood stem cells 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Polymerase (RNA) II (DNA directed) polypeptide L...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
Biology Products: